Oral Fingolimod (FTY720) for Relapsing Multiple SclerosisLudwig Kappos, Ernst W. Radue, Jack P. Antel et al.|New England Journal of Medicine|2006Cited by 1.1k
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysisJennifer L. McQuade, Michael A. Davies, Nageshwar Budha et al.|The Lancet Oncology|2018Cited by 658
Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn’s Disease After Ileocolonic ResectionMiguel Regueiro, Pierre Desreumaux, Brian G. Feagan et al.|Gastroenterology|2016Cited by 329
Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected <i>BRAF</i> V600–Mutant Stage III MelanomaAxel Hauschild, Georgina V. Long, Reinhard Dummer et al.|Journal of Clinical Oncology|2018Cited by 255
Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600–Mutant Unresectable or Metastatic MelanomaReinhard Dummer, Dirk Schadendorf, Georgina V. Long et al.|Zurich Open Repository and Archive (University of Zurich)|2022Cited by 146